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Abstract
The organic anion transporting polypeptide (OATP) family of transporters has been implicated in prostate cancer disease
progression probably by transporting hormones or drugs. In this study, we aimed to elucidate the expression, frequency,
and relevance of OATPs as a biomarker in hormone-dependent cancers. We completed a study examining SLCO1B3,
SLCO1B1 and SLCO2B1 mRNA expression in 381 primary, independent patient samples representing 21 cancers and normal
tissues. From a separate cohort, protein expression of OATP1B3 was examined in prostate, colon, and bladder tissue. Based
on expression frequency, SLCO2B1 was lower in liver cancer (P=0.04) which also trended lower with decreasing
differentiation (P=0.004) and lower magnitude in pancreatic cancer (P=0.05). SLCO2B1 also had a higher frequency in
thyroid cancer (67%) than normal (0%) and expression increased with stage (P=0.04). SLCO1B3 was expressed in 52% of
cancerous prostate samples and increased SLCO1B3 expression trended with higher Gleason score (P=0.03). SLCO1B3
expression was also higher in testicular cancer (P=0.02). SLCO1B1 expression was lower in liver cancer (P=0.04) which
trended lower with liver cancer grade (P=0.0004) and higher with colon cancer grade (P=0.05). Protein expression of
OATP1B3 was examined in normal and cancerous prostate, colon, and bladder tissue samples from an independent cohort.
The results were similar to the transcription data, but showed distinct localization. OATPs correlate to differentiation in
certain hormone-dependent cancers, thus may be useful as biomarkers for assessing clinical treatment and stage of disease.
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Introduction
Organic anion-transporting polypeptides (OATPs; encoded by
SLCO genes) are involved in hepatocyte influx mechanisms and are
overexpressed in some cancers [1,2,3]. Known ligands of the
OATP family include myriad endogenous substrates such as:
steroids (i.e., estrogen sulfate, testosterone, and DHT), bile acids,
and peptides [4]. OATP family members also influx a variety of
pharmaceuticals, including (but not limited to): antihistamines,
blood-glucose lowering drugs, statins, heart medications, and
anticanceragents[4].Therefore,OATPsareemergingasimportant
transporters in the treatment of cancer from the standpoints of drug
distribution and disease outcomes, and it is expected that many
more endogenous and exogenous substrates will be identified by
future studies.
Expression and genetic variation in OATPs have been associated
with clinical outcomes in patients with prostate cancer. Both
SLCO1B3 and SLCO2B1 have been related to a shorter time to
androgen deprivation therapy failure and decreased overall survival
in patients with hormone responsive prostate cancer, and castration
resistant prostate cancer (CRPC) respectively [1,5,6]. Mechanisti-
cally, these associations might be attributed to genetic variation in
androgen (or other steroid hormone) influx mechanisms that
increase androgen scavenging during androgen deprivation
therapy (ADT) [1]. Although OATP1B3 influx mechanisms are
still unknown in colon cancer, there is sufficient evidence suggesting
that OATP1B3 is overexpressed in a large proportion of colon
tumors, and that this overexpression contributes to cell survival in
the presence of oxalaplatin and camptothecin; the latter effect may
be related to p53 expression [2].
OATPs have also been shown to contribute to systemic
variation in anti-cancer drug treatments. For instance, OATP1B3
was initially identified as a high-affinity hepatocellular transporter
of paclitaxel, and is also the most efficient liver uptake transporter
of docetaxel [7,8]. OATP1B1 and OATP1B3 also influx SN-38
[4], and this transport may have implications in the treatment of
colon cancer [2]. However, the tumor influx mechanisms have yet
to be explored for these drugs in relevant diseases, and this effort
has been hindered by the lack of studies that have evaluated tumor
expression of OATPs.
As OATPs have been implicated in both the etiology and
treatment of prostate cancer and colon cancer, we undertook to
explore whether or not these OATPs are also overexpressed in
other tumor types and whether or not OATP expression could
serve as a biomarker for tumor development or tumor aggressive-
ness in certain diseases.
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Clinical samples
Samples were obtained from Origene (TissueScan Cancer
Survey Panel III, Rockville, MD). Briefly, RNA was isolated from
patients of mixed age, clinical diagnosis, and with various tumor
stages. cDNA was created, normalized to actin B, checked for
contamination and sensitivity (as determined by the manufactur-
er). The panel includes 384 samples encompassing 22 cancers and
matched normal tissues. The numbers of samples corresponding to
different tumor types and the number of samples derived from
different tumor grades are reported in Table S1.
Determination of mRNA expression
SLCO1B3 (Hs00251986_m1), SLCO2B1 (Hs00200670_m1),
and SLCO1B1 (Hs00272374_m1) expression levels were analyzed
using Taqman Gene Expression Assays (Applied Biosystems).
Briefly, the primers were mixed with Taqman Master Mix (No
Amp Erase) and distilled water then added to the samples. The
plates were run in duplicate on Mx3005P QPCR System (Agilent
Technologies) for 10 minutes 95uC then cycling for 42 cycles of 30
seconds for 95uC and 1 minute 60uC then FAM (ROX reference)
reading after every cycle. Expression of each SLCO gene was
normalized to actin by determining the cycle threshold (Ct) for
each gene by the following formula: 2‘-(CtSLCO-CtActinB)*10
5 (i.e.,
the DCt). In cases where mRNA samples were below the LLOQ,
the samples were noted to have SLCO mRNA levels at just below
LLOQ (i.e. 42.1 cycles) and were normalized to actin as described
above. This is considered to be a conservative adjustment as there
were a large number of samples with undetectable SLCO mRNA
levels that were likely to be significantly lower than the LLOQ.
Determination of protein expression
Tissue section arrays for bladder, colon, and prostate were
obtained from Pantomics (Richmond, CA). The prostate tumor
tissue array includes benign prostatic hyperplasia and cancerous
tissue; the normal and tissue samples were not matched per patient.
Bladder and colon cancer arrays were also obtained from the above
company and these included uninvolved and cancerous tissue. All
tissues were obtained from surgical resection and fixed in 10%
neutral buffered formalin for 24 hours. Slides were preparing by
bakingfor 1 hour 60uC beforeremovingthe paraffininxylene, then
prepping for staining in 100% ethanol, 95% ethanol, 70% ethanol,
and distilled water washes. One slide per set was stained with
hematoxylin and eosin. The remaining slides were processed for
immunoflourescence by placing in 95uC 10 mM sodium citrate
buffer for 5 minutes then allowing to cool for 20 minutes. The slides
were blocked for 30 minutes before primary antibody against
OATP8 was applied 1:100 (Progen) at 4uC overnight. Slides were
washed in Tris-Buffered Saline Tween before applying the
secondary FITC goat anti-mouse 1:400 (Abcam) for 2 hours. Slides
were washed again in TBST and mounted with VectaShield
(Vector Labs) with DAPI. Images were taken on an Olympus BX51
microscope with UPlanFl 40x and 10x lenses. InSight Firewire
camera and Spot version 4.5 imaging software were used to capture
images. Adobe Photoshop CS3 version 10 was used for after-
capture edits where all photos were processed the same.
Statistical considerations
Comparisons between the frequency of SLCO or OATP
expression in normal versus tumor tissues was conducted using
Fisher’s exact test. Comparisons were made between the
magnitude of SLCO mRNA expression versus the corresponding
normal tissue using the Wilcoxon rank sum test; these data are
reported as the mean DCT (95% confidence interval; CI) and
corresponding fold-change from normal tissue. The Cochran-
Armitage trend test was employed to determine if the frequency of
SLCO or OATP expression varied with tumor cell differentiation
or stage, while the Jonckheere-Terpstra trend test was used to
determine if the magnitude of SLCO mRNA expression varied
with tumor cell differentiation or stage. Assessment of protein
expression magnitude was not possible, although we did note if
tumors expressed detectable levels of OATP1B3 or not. Only two-
tailed P-values are reported, and given the exploratory nature of
this study, P-values are reported as significant if P,0.05; however,
it should be noted that conservative non-parametric and exact tests
were performed in order to reduce the potential for false positives.
Results
Expression of SLCO mRNA in normal and tumor tissues
We first hypothesized that SLCO expression would be a
biomarker for multiple different hormone-dependent tumor types.
To this end, SLCO mRNA expression was determined in samples
derived from normal human tissue and corresponding tumor
tissue. Expression frequencies were determined for SLCO1B3,
SLCO1B1, and SLCO2B1, and the percent of normal or tumor
tissues expressing SLCOs are reported (see Figure 1A–C
respectively). Prostate tumors expressed SLCO1B3 much more
frequently than normal prostate tissues (62% vs. 0%, n=21 and
n=5 respectively; P=0.04) and more frequently with increasing
Gleason score (P=0.03). In addition, SLCO1B3 expression was less
frequent in testicular tumors (21% vs. 67%, n=19 and n=6
respectively; P=0.06). SLCO1B1 was frequently expressed signif-
icantly higher with decreasing differentiation in colon tumors
(P=0.04). SLCO2B1 was not expressed significantly different in
cancer compared to normal tissue. In addition to the above
observations, it should be noted that there were several cases
where there was no SLCO expression in normal tissues, but
expressed in cancerous samples. While not statistically significant
due to low power, some tumor tissues have SLCO expression and
should be evaluated more closely in future studies. These tumors
included (for SLCO1B3); colon, endometrium, esophagus, gastro-
esophageal, kidney, ovary, and thyroid, (for SLCO1B1); cervix,
endometrium, esophagus, gastroesophageal, lung, lymph, ovary,
thyroid, bladder, and uterus (for SLCO2B1); colon, bladder (See
Table S1 for comprehensive data analysis).
As some tumor tissues had similar SLCO expression frequencies
as normal tissues, we also ascertained if the magnitude of SLCO
expression was different for SLCO1B1, SLCO1B3, and SLCO2B1
(see Figure 1D–F respectively). Significant differences in
expression levels (i.e. mean DCtnormal (95%CI) vs. DCttumor
(95%CI)) between normal and tumor tissue were observed for
SLCO1B3 in prostate cancer [0.23 (0.23 to 0.23) versus 104 (44 to
164); 45.7-fold increase; P=0.03] and testicular cancer [174 (0.3
to 350) versus 14.0 (0.3 to 26); 12.8-fold decrease; P=0.01].
Significant increases were seen for SLCO1B1 in liver cancer
[396000 (225000 to 567000) versus 161000 (41000 to 280000); 2.4
fold decrease; P=0.04]. SLCO2B1 expression decreased signifi-
cantly in pancreatic cancer [27.5 (9.5 to 45) versus 9.1 (5.5 to
12.8); 3.0 fold decrease; P=0.05] and liver cancer [47.3 (16.1 to
78) versus 17.0 (4.9 to 29); 2.7 fold decrease; P=0.04]. A more
comprehensive analysis of expression differences is provided in
Table S1.
OATP expression versus tumor differentiation and stage
Since previous reports indicated that certain OATPs were
involved in disease etiology and progression [1,2,5], we hypoth-
OATP Family Members as Cancer Biomarkers
PLoS ONE | www.plosone.org 2 May 2011 | Volume 6 | Issue 5 | e20372Figure 1. Expression profile of SLCOs in normal and neoplastic tissues. Data are first expressed as a percentage of tissues with mRNA
expression of A) SLCO1B3 B) SLCO1B1, and C) SLCO2B1, and then as the magnitude of normalized mRNA expression of D) SLCO1B3,E )SLCO1B1, and F)
SLCO2B1.*-P ,0.05, ** - P,0.01 for Fisher’s Exact and Wilcoxon Rank Sum Tests respectively.
doi:10.1371/journal.pone.0020372.g001
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tumor differentiation or stage. For prostate tumors, expression of
SLCO1B3 increased along with Gleason score up to 67-fold [mean
DCT (95%CI) =0.23 (0.23 to 0.23), 2.6 (24 to 9.2), 8.5 (20.7 to
17.7), 15.5 (213 to 44), 15.0 (2.4 to 27), for normal tissue, and
Gleason =6, 7, 8, 9 respectively; P=0.03; Figure 2A]. SLCO1B1
expression was related to differentiation in liver cancer (395000
(225000 to 567000), 175000 (4300 to 310000), 47000 (11000 to
83000), and 3500 (N/A) for normal tissue, and well, moderately,
and poor differentiated tumor tissue respectively; P=0.0004,
Figure 2B)u pt oa274 fold difference. SLCO1B1 expression was
also related colon cancer (0.23 (0.23 to 0.23), 0.23 (0.23 to 0.23),
1.3 (21.0 to 3.6), and 2.9 (N/A) for normal tissue, and well,
moderately, and undifferentiated tumor tissue respectively;
P=0.05, Figure 2C) up to a 12.5 fold difference. SLCO2B1
expression was also correlated negatively to differentiation in liver
Figure 2. SLCO mRNA expression correlates to differentiation in cancer. SLCO1B3 mRNA expression by differentiation in A) prostate P=0.03.
SLCO1B1 expression in B) liver P=0.0004, C) colon P=0.05. SLCO1B2 expression in D) liver P=0.005. E) SLCO2B1 expression by stage in thyroid
P=0.04. All were found as signifcant correlations by the Jonckheere-Terpstra trend test.
doi:10.1371/journal.pone.0020372.g002
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A) for normal tissue and well, moderately, and poor differentiated
tumor tissue respectively; P=0.005) up to a 26-fold change
(Figure 2D).
The expression and frequency data was also analyzed with
respect to stage. SLCO2B1 expression increased with stage up to a
29 fold-difference in thyroid cancer (P=0.04). See Figure 2E. For
normal and stage I, II, III, IVA the increase was 0.23 (0.23 to
0.23), 1.4 (0.6 to 2.1), 5.6 (20.8 to 12), 6.7 (20.4 to 14), 1.0 (N/A).
Due to limited samples numbers for each stage no other
relationships were statistically significant. However, other notable
trends were SLCO2B1 decreased expression by stage in pancreatic
cancer, SLCO1B3 increased frequency by stage in prostate cancer,
and SLCO1B1 decreased expression by stage in liver cancer. For
the full data set see Table S2.
OATP protein expression versus tumor differentiation
To determine if OATP translation is similar to the quantitiative
PCR, we conducted immunoflourescence on tissue samples from
prostate, colon, and bladder cancer to detect OATP1B3.
OATP2B1 was not chosen for protein validation because it is
expressed both in normal and cancerous tissues. For prostate
tumors, expression of OATP1B3 was primarily observed in prostate
tumors and not normal tissues (P=0.001; Figure 3A–E and
Table 1) and was highly expressed in the stroma. Moreover, the
Figure 3. Tissue staining of OATP1B3 expression in cancer. Concurrent tissue sections stained with hematoxylin and eosin (left panel) and
immunofluoresence (right panel) for OATP1B3. OATP1B3 is detected with FITC, in green, and nuclei are stained with DAPI, in blue. Prostate tissues
comprising, BPH, and tumors of varying grade are reported as follows: A) benign prostatic hyperplasia, B) gleason 6, C) gleason 7, D) gleason 8, E)
gleason 9. Bladder tissue sections are derived from F) normal bladder, G) grade II, H) grade III bladder tumors. Finally, colon tissue from I) normal
colon, J) grade II (10x magnification), K) grade III colon tumors are disclosed. All photos were taken at 40x magnification unless otherwise noted.
doi:10.1371/journal.pone.0020372.g003
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Gleason score (P=0.001; Table 1). Expression was also more
frequent incoloncancer(P=0.06,Figure3F–H andTable1) and
trended towards an association with a statistically significant higher
incidence of expression in colon cancer by Cochran-Armitage test
(P=0.02; Table 1). OATP1B3 expression was observed primarily
in the vasculature in colon cancer and invasive, cancerous epithelial
cells in bladder cancer. Consistent withthe mRNA data, OATP1B3
expression was not associated with increasing histological grades of
bladder cancer (P=0.34; see Table 1 and Figure 3I–K), but
trended towards an association with bladder cancer grades despite a
low number of samples (P=0.07; see Table 1).
Discussion
SLCO (and OATP) overexpression has already been shown to be
an important factor in colon and prostate cancer (1,2); moreover
variation in OATP function [1] appears to be related to clinical
outcome of endocrine therapy in prostate cancer [5] as well as
overall survival of men CRPC [1]. Previous reports also
demonstrated significant decreases in expression of SLCOs in
hepatocellular carcinoma; this phenomenon is most likely
associated with the reduction of metabolic function due to
dedifferentiation in liver tumors derived from patient samples
[9]. The present study confirms the above observations and
demonstrates for the first time that SLCO expression variability is
also associated with several other tumor types, including: colon
cancer, liver cancer, pancreatic cancer, prostate cancer, testicular
cancer, and thyroid cancer. Despite previously published reports,
SLCO1B3, SLCO2B1, and SLCO1B1 were not highly expressed in
our breast cancer samples [10,11].
We also demonstrated that SLCO1B3 expression levels are
significantly related to the Gleason score in prostate cancer.
SLCO1B1 expression levels were significantly related to the degree
of differentiation in liver and colon cancers. SLCO2B1 expression
was also significantly related to liver and thyroid cancer.
Immunoflourescent for OATP1B3 showed distinct localization in
colon, bladder, and prostate cancers. The vasculature was stained
for OATP1B3 only in high-grade colon cancer, cancerous
epithelia in bladder cancer, and the stroma in prostate cancer.
Thus OATP1B3 could be involved either directly or indirectly
supporting carcinogensis depending on the cancer type. Previously
mentioned studies suggest that variation in the expression of
OATPs is likely involved in underlying disease etiology through
Table 1. OATP Expression in Immunoflourescent Tissue
Sections.
Tissue Differentiation Express Total P value
Prostate 0.001
BPH 7 (26%) 27 0.001
Gleason 4 4 (44%) 9
Gleason 5 4 (57%) 7
Gleason 6 5 (71%) 7
Gleason 7 4 (100%) 4
Gleason 8 16 (64%) 25
Gleason 9 9 (64%) 14
Colon 0.06
Normal 7 (21%) 32 0.02
II–I3 (38%) 8
II 4 (50%) 8
III 6 (50%) 12
Bladder 0.34
Normal 5 (21%) 24 0.07
II–I1 (17%) 6
III–II 3 (33%) 9
III 4 (50%) 8
P-value = Fischer’s exact or Cochran-Armitage trend test.
doi:10.1371/journal.pone.0020372.t001
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OATPs influx several steroid hormones (i.e. DHEA, testoster-
one, DHT, and estrogen-sulfate) that underlie the etiology of
several different diseases. For clarity, a table of selected OATP
substrates is included (Table 2). Testosterone is a substrate for
OATP1B3 and may explain its role in prostate[1], bladder
[12,13], and testicular [14] tumor development and progression.
OATP1B3 and OATP1B1 also influx estrone-3-sulfate and
thyroxine and these hormones play a major role in ovarian [15]
and thyroid cancers [16] respectively. The OATP substrates could
also inhibit cancer growth, thus be negatively selected against as
the cancer progresses. For example, DHEA-S inhibits pancreatic
cancer growth [17,18], which might explain the observation that
SLCO2B1 expression is reduced in pancreatic cancer. In addition,
the present data may also indicate a previously unknown role for
the OATP-transported hormones in these cancers. Finally,
OATPs transport a wide range of substances, thus there could
also be unidentified or uncharacterized substrates that influence
disease progression in the above-mentioned cancers.
Although it remains poorly explored, OATP expression may
influence treatment success in certain cancer types (Table 2).
OATP1B3 influxes docetaxel, paclitaxel, imatinib, irinotecan, SN-
38, and methotrexate while OATP1B1 influxes ketoconazole,
paclitaxel, and SN-38. OATP2B1 drug substrates remain poorly
explored. Interestingly, these drugs are often very effective in
treating metastatic diseases that develop as a result of the primary
tumors that were evaluated herein. Docetaxel is approved for the
treatment of CRPC and non-small cell lung cancer (NSCLC) and
OATP1B3 is highly expressed in both prostate and lung tumors
suggesting that the effectiveness of docetaxel treatment in these
diseases may be, in part, due to sensitivity to docetaxel resulting
from the underlying disease etiology. Using prostate tumors as an
example, it appears that OATP1B3 is overexpressed during
disease development in the primary tumor, facilitates the survival
of metastatic prostate lesions during androgen deprivation therapy
[1,5,19], and may be involved in the sensitivity of CRPC tumors
towards docetaxel due to increased uptake. Moreover, SLCO1B1
overexpression in prostate tumors may also explain the sensitivity
of prostate cancer to ketoconazole. Similar relationships may be
proposed for use of paclitaxel (in ovarian, lung, and esophageal
tumors), imatinib (in gastroesophageal tumors), irinotecan and
SN38 (in colon and lung tumors), and methotrexate (in lung
tumors). Moreover, previous data have indicated that treatment-
and disease-related SLCO1B3 expression in liver result in
differences in pharmacokinetic exposure to drugs [20]. We
therefore propose the hypothesis that OATPs are involved in
multidrug sensitivity through influx mechanisms and drugs
targeting OATP influx may be more effective in certain diseases
and treatment contexts based on OATP expression in the tumor
and in the liver.
Limitations in this work include low positive tumors for several
sample sets, so complex analysis on differentiation and expression
could not be adequately assessed. In addition, little to no
differentiation data was available for testis, thyroid, lymph, uterus,
and gastroesophageal samples. As mentioned above, there are
several substrates of OATPs that may explain its role in the
identified cancers so further follow up studies should include
clinical validation as well as functional studies related to substrate
transport. Clinical follow up investigation for individual cancers is
clearly warranted and should include examining expression in
larger cohorts and confirming the effect of transported substrates
on disease progression in thyroid, endometrial, lung, ovary,
pancreas, testis, and bladder cancers.
This is the first study indicating that SLCO1B1, SLCO1B1, and
SLCO2B1 is significantly expressed (or expression is reduced) in a
variety to tumors, including: colon cancer, liver cancer, pancreatic
cancer, prostate cancer, testicular cancer, and thyroid cancer. We
also propose that OATP expression may be a biomarker in
prostate and colon cancers, and knowledge of tumor expression of
OATPs could guide chemotherapy treatment. We conclude
OATP expression may have implications on disease etiology and
effectiveness of treatment, and should be studied further for its
expression in cancer.
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